Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...

Spherico and the Syneos Health Value & Access team interviewed 25 pharmacy and medical directors. The fifth annual Payer ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar during ...

Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for ...

Nintendo has added two more Game Boy titles to its Switch Online subscription catalogue - and you can play them right now. 1994 classic Donkey Kong is the star of the show here - the highly ...

A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar ...